



Tools for Cancer Liaison Physicians

Reported Measure Compliance

The Cancer Program Practice Profile Reports (CP³R) provides retrospective and comparative information to assess adherence to and consideration of standard of care therapies for major cancers. The aim is to empower clinicians, administrators and other staff to work cooperatively and collaboratively to identify problems in practice and deliver and to implement best practices which will diminish disparities in care across CoC accredited cancer programs.

Current estimated performance rates are included for breast, colon and rectum cases diagnosed 2004-2010. This application allows programs to first assess longitudinal annual reported compliance, to assess and update specific case compliance and to compare reported compliance to other CoC accredited cancer programs.

Reported Performance Measures

- Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.
- Combination chemotherapy is considered or administered within four months (120 days) of diagnosis for women under age 70 with AJCC T1cN0M0 or Stage II or III hormone receptor negative breast cancer.
- Tamoxifen or third generation aromatase inhibitor is considered or administered within one year (365 days) of diagnosis for women with AJCC T1cN0M0 or Stage II or III hormone receptor positive breast cancer.
- At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.
- Adjuvant chemotherapy is considered or administered within four months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer.
- Radiation therapy is considered or administered within six months (180 days) of diagnosis for patients under the age of 80 with clinical or pathologic AJCC T4N0M0 or Stage III and who are receiving surgical resection for rectal cancer.

Select Breast & Colorectal Measures		Estimated Performance Rates (click rate for comparisons)							Case Review
		2004	2005	2006	2007	2008	2009	2010	
BREAST	Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. [BCS/RT]	80.2%	80.2%	84.6%	80.5%	92.9%	91.1%	78.8%	
	Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c NO MO, or Stage II or III ERA and PRA negative breast cancer. [MAC]	82.8%	87.5%	86.2%	88.2%	95.8%	91.7%	66.7%	
	Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c NO MO, or Stage II or III ERA and/or PRA positive breast cancer. [HT]	78.6%	84%	79.3%	84.8%	87.4%	80.2%	65.3%	
COLON	Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer. [ACT]	90.5%	81.8%	91.7%	94.1%	78.6%	100%	86.7%	
	At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. [12RLN]	54.4%	56.6%	70.8%	72.9%	90.7%	86.2%	86.4%	
RECT	Radiation therapy is considered or administered within 6 months (180 days) of diagnosis for patients under the age of 80 with clinical or pathologic AJCC T4N0M0 or Stage III receiving surgical resection for rectal cancer. [AdjRT]	100%	60%	88.9%	100%	100%	100%	40%	

How to interpret longitudinal estimated performance rates:

The first screen in the CP³R application shows reported compliance to the included measures from 2004-2010. This information can be assessed for changes in reported compliance over time.

NOTE: Programs may observe lower than expected compliance rates when data is initially uploaded in the CP³R application, as in the figure above. This may signify that data validation is required to ensure complete adjuvant therapy information is documented. Individual case review may be initiated by clicking on the associated measure abbreviation under the right column 'Case Review.'

Running the Report:

Comparisons of reported compliance may be generated by:

- Clicking on the reported compliance for a specific measure and diagnosis year of interest.

NCDB Demo Facility, Townsville, IL				
FACILITY SELECTION	ALL MEASURES SUMMARY	THIS MEASURE SUMMARY		
Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. [BCS/RT]		Diagnosis Year: 2010 (Last Update: Mar 14, 2013 12:03:15 AM CST)		
		Perf. Rate	95% CI	Cases
My Cancer Program		78.8 %	(68.9 - 88.7)	66
My State (IL)		92.2 %	(91.2 - 93.2)	2798
My ACS Division (Illinois)		92.2 %	(91.2 - 93.2)	2798
My Census Region (Greatlakes)		93.3 %	(92.8 - 93.8)	9410
My CoC Program Type (THCP)		90.6 %	(90.2 - 91)	16898
All CoC Approved Programs (ALL)		90.9 %	(90.7 - 91.1)	53244

Intepreting the Report

This cancer program has a reported compliance of 78.8% with an associated 95% confidence interval of 68.9%-88.7% for radiation therapy following breast conserving surgery. This is significantly lower than the 90.9% reported compliance for all CoC accredited programs. It is also lower than the 90% benchmark requirement set in the CoC Standards.

Next Steps:

It is the responsibility of the CLP to report and discuss the facility's performance as well as perform a quality-related audit for any metric(s) which fall below the levels of compliance required by the CoC Standards.

If reported compliance is lower than expected, first a data review of cases should be initiated to ensure all adjuvant therapy information is documented. Updates to the any case may be made directly into the CP³R system by the hospital registrar. Reported compliance rates will update overnight.

An assessment of reasons for non-concordant cases may be initiated to determine if opportunities for quality improvement are present.